Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results

Benzinga

02/25

Hims & Hers Health Inc (NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.

Hims & Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.

"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health," said Andrew Dudum, co-founder and CEO of Hims & Hers Health.

Hims & Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.

Hims & Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.

These analysts made changes to their price targets on Hims & Hers Health following earnings announcement.

Evercore ISI Group analyst Mark Mahaney maintained Hims & Hers Health with an In-Line rating and lowered the price target from $33 to $24.
Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.
TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.
Citigroup analyst Daniel Grosslight maintained Hims & Hers Health with a Sell and lowered the price target from $16.5 to $13.25.

Considering buying HIMS stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614329741"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614329741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614329741?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 01:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614329741","market":"us","top_or_hot":-1,"title":"Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Hims &amp; Hers Health Inc </strong>(NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.</p>\n<p>Hims &amp; Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.</p>\n<p>\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.</p>\n<p>Hims &amp; Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.</p>\n<p>Hims &amp; Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Hims &amp; Hers Health following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Mark Mahaney maintained Hims &amp; Hers Health with an In-Line rating and lowered the price target from $33 to $24.</li>\n<li>Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.</li>\n<li>TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.</li>\n<li>Citigroup analyst Daniel Grosslight maintained Hims &amp; Hers Health with a Sell and lowered the price target from $16.5 to $13.25.</li>\n</ul>\n<p><strong>Considering buying HIMS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"507\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572.png 1203w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Analysts Cut Their Forecasts After Q4 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-02-25 01:46</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Hims &amp; Hers Health Inc </strong>(NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.</p>\n<p>Hims &amp; Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.</p>\n<p>\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.</p>\n<p>Hims &amp; Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.</p>\n<p>Hims &amp; Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Hims &amp; Hers Health following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Mark Mahaney maintained Hims &amp; Hers Health with an In-Line rating and lowered the price target from $33 to $24.</li>\n<li>Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.</li>\n<li>TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.</li>\n<li>Citigroup analyst Daniel Grosslight maintained Hims &amp; Hers Health with a Sell and lowered the price target from $16.5 to $13.25.</li>\n</ul>\n<p><strong>Considering buying HIMS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"507\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572.png 1203w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50825141/hims-hers-health-analysts-cut-their-forecasts-after-q4-results","article_id":"2614329741","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614329741","pubTimestamp":1771955163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","BK4196":"保健护理服务"},"translate_title":"Hims&Hers Health分析师在第四季度业绩公布后下调了预测","themeId":"2911eb51361e3b2a673f8e81d788a13a","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1.98,"HIMZ":0.6,"HMYY":0.6,"HIMY":0.6,"HIYY":0.6},"content_text":"Hims & Hers Health Inc (NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.\nHims & Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.\n\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims & Hers Health.\nHims & Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.\nHims & Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.\nThese analysts made changes to their price targets on Hims & Hers Health following earnings announcement.\n\nEvercore ISI Group analyst Mark Mahaney maintained Hims & Hers Health with an In-Line rating and lowered the price target from $33 to $24.\nTruist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.\nTD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.\nCitigroup analyst Daniel Grosslight maintained Hims & Hers Health with a Sell and lowered the price target from $16.5 to $13.25.\n\nConsidering buying HIMS stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}